Biogen seeks to dismiss amended product-hopping claims in US pharma case
( October 10, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Biogen told a US federal judge that even though it’s doubled in length, plaintiffs’ second amended complaint suffers from the same flaws that led the court to dismiss the previous one, moving to dismiss claims that it used a “market switch” to unlawfully impair competition from generic versions of its brand-name drug Tecfidera. It argued that “plaintiffs’ claims are barred because they are (at best) indirect purchasers seeking to recover for alleged manufacturer overcharges traveling through wholesalers and/or retailers on to patients and health plans.”See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.